The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
SBRT of all known metastatic sites was associated with improved PFS and OS among children and young adult patients with inoperable sarcoma.
Nivolumab plus ipilimumab demonstrated antitumor activity among patients with either primary or secondary angiosarcoma, according to phase 2 data.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Radioresistant sarcoma may require treatment intensification.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
